通用名称为SOMATULINE DEPOT
兰瑞肽60mg，90mg，120毫克，长期释放的SC INJ soln。

法律分类：
接收

药理班级SOMATULINE DEPOT
生长抑素类似物。

制造商SOMATULINE DEPOT
Tercica公司
主治为SOMATULINE DEPOT
长期治疗的肢端肥大症患者谁也进行了充分的反应或不能手术和/或放疗治疗。

成人剂量为SOMATULINE DEPOT
深SC注射给到上级的臀部外部象限。旋转注射部位。正常范围：60 - 120毫克，每4周。最初90mg，每4周3个月。经过3个月，调整如下：≤1ng/mL GH，IGF - 1正常，临床症状控制：降低至60mg，每4周; GH> 1ng/mL≤2.5ng/mL到GH，IGF - 1正常，临床症状控制：保持在90mg每4周; GH> 2.5ng/mL，IGF - 1升高和/或临床症状失控：增加120毫克，每4周。如果在60mg或90mg控制，可考虑延长120毫克每6或8周给药间隔;获得GH和IGF - 1水平的变化疗程6周后评价的回应。中度至重度肾功能或肝功能不全：开始60mg，每4周3个月，调整后的基础上GH和/或IGF - 1的水平。注意在考虑延长给药间隔治疗。

儿童剂量为SOMATULINE DEPOT
不推荐。

警告/注意事项为SOMATULINE DEPOT
糖尿病。甲状腺功能减退。心血管疾病。肾或肝损害。监视器生长激素（GH），IGF - 1的水平，甲状腺功能，胆囊，葡萄糖。妊娠（Cat.C）。护理母亲。

相互作用的SOMATULINE DEPOT
Potentiates溴隐亭，CYP450底物（如奎尼丁，特非那丁），心动过缓诱导药物（如β-阻断剂），调整剂量。拮抗环孢素（调整剂量）。可能需要调整抗糖尿病药物。

为SOMATULINE DEPOT不良反应
腹泻，胆石症，腹痛，恶心，注射部位反应，胆泥，胆结石，高血糖，低血糖，窦性心动过缓，高血压，贫血;罕见：甲状腺功能减退。

如何SOMATULINE DEPOT提供？
一次性使用预充注射器- 1

SOMATULINE DEPOT

Generic Name for SOMATULINE DEPOT

Lanreotide 60mg, 90mg, 120mg; prolonged-release soln for SC inj.

Legal Classification:

Rx

Pharmacological Class for SOMATULINE DEPOT

Somatostatin analogue.

Manufacturer of SOMATULINE DEPOT

Tercica, Inc.

Indications for SOMATULINE DEPOT

Long-term treatment of acromegaly in patients who have had an inadequate response or cannot be treated with surgery and/or radiotherapy.

Adult dose for SOMATULINE DEPOT

Give by deep SC injection into the superior external quadrant of the buttock. Rotate inj site. Usual range: 60–120mg every 4 weeks. Initially 90mg every 4 weeks for 3 months. After 3months, adjust as follows: GH≤1ng/mL, IGF-1 normal and clinical symptoms controlled: reduce to 60mg every 4 weeks; GH>1ng/mL to GH≤2.5ng/mL, IGF-1 normal and clinical symptoms controlled: maintain at 90mg every 4 weeks; GH>2.5ng/mL, IGF-1 elevated and/or clinical symptoms uncontrolled: increase to 120mg every 4 weeks. If controlled on 60mg or 90mg, may consider extended dosing interval of 120mg every 6 or 8 weeks; obtain GH and IGF-1 levels 6 weeks after regimen change to evaluate response. Moderate-to-severe renal or hepatic impairment: initially 60mg every 4 weeks for 3 months; adjust thereafter based on GH and/or IGF-1 levels. Caution when considering extended dosing interval treatment.

Children's dosing for SOMATULINE DEPOT

Not recommended.

Warnings/Precautions for SOMATULINE DEPOT

Diabetes. Hypothyroidism. Cardiovascular disease. Renal or hepatic impairment. Monitor growth hormone (GH), IGF-1 levels, thyroid function, gallbladder, glucose. Pregnancy (Cat.C). Nursing mothers.

Interactions for SOMATULINE DEPOT

Potentiates bromocriptine, CYP450 substrates (eg, quinidine, terfenadine), bradycardia-inducing drugs (eg, β-blockers); adjust doses. Antagonizes cyclosporine (adjust dose). May need to adjust antidiabetic agents.

Adverse Reactions for SOMATULINE DEPOT

Diarrhea, cholelithiasis, abdominal pain, nausea, inj site reactions; gallbladder sludge, gallstones, hyperglycemia, hypoglycemia, sinus bradycardia, hypertension, anemia; rare: hypothyroidism.

How is SOMATULINE DEPOT supplied?

Single-use pre-filled syringe—1